(Q37147762)

18 August 2017

1 reference

title

Targeted therapy of cancer: new roles for pathologists in colorectal cancer (English)

1 reference

18 August 2017

1 reference

Stanley R Hamilton

1

1 reference

18 August 2017

1 May 2008

1 reference

18 August 2017

1 reference

18 August 2017

21 Suppl 2

1 reference

18 August 2017

S23-30

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2008.14

18 August 2017

0 references

cites work

Pharmacogenomics of thymidylate synthase in cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Systematic review of microsatellite instability and colorectal cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Adjuvant therapy in colon cancer--what, when and how?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Adjuvant chemotherapy of stage III colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

New approaches to the adjuvant therapy of colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Molecular markers that predict response to colon cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Predicting the outcome of chemotherapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Pharmacogenomics in colorectal carcinomas: future perspectives in personalized therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Clinical application of pharmacogenetics in gastrointestinal diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Cancer survival: time to get moving? Data accumulate suggesting a link between physical activity and cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Radiation therapy and combined modality treatment of gastrointestinal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

The prognostic significance of thymidylate synthase and dihydropyrimidine dehydrogenase in colorectal cancer of 303 patients adjuvantly treated with 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Intratumoral molecular or genetic markers as predictors of clinical outcome with chemotherapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Methyl-group metabolism and the response of colorectal cancer to 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Thymidylate synthase pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Genomic copy number changes affecting the thymidylate synthase (TYMS) gene in cancer: a model for patient classification to aid fluoropyrimidine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Screening for dihydropyrimidine dehydrogenase deficiency: to do or not to do, that's the question

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

How may anticancer chemotherapy with fluorouracil be individualised?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Update on capecitabine in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Current status of excision repair cross complementing-group 1 (ERCC1) in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Irinotecan in the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Pharmacogenomics of colorectal cancer prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

The role of bevacizumab as first-line therapy for colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Panitumumab in colon cancer: a review and summary of ongoing trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Molecular determinants of cetuximab efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Lymph node status and TS gene expression are prognostic markers in stage II/III rectal cancer after neoadjuvant fluorouracil-based chemoradiotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

Pharmacogenomics and colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

Thymidylate synthase expression in colon carcinomas with microsatellite instability

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

Which gene is a dominant predictor of response during FOLFOX chemotherapy for the treatment of metastatic colorectal cancer, the MTHFR or XRCC1 gene?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

Vascular endothelial growth factor inhibitors in colon cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2008.14

7 January 2021

10.1038/MODPATHOL.2008.14

Identifiers

DOI

1 reference

18 August 2017

1 reference

PubMed ID

18437170